- Home
- RDI vs NRSN Comparison
RDI vs NRSN Comparison
Compare RDI & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RDI | NRSN |
|---|---|---|
| Founded | 1937 | 2017 |
| Country | United States | Israel |
| Employees | 2025 | 15 |
| Industry | Movies/Entertainment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.8M | 24.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | RDI | NRSN |
|---|---|---|
| Price | $1.10 | $0.78 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 22.6K | ★ 187.1K |
| Earning Date | 05-14-2026 | 03-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $16.25 | N/A |
| Revenue Next Year | $4.04 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.94 | $0.63 |
| 52 Week High | $1.65 | $2.60 |
Technical Indicators
Market Signals| Indicator | RDI | NRSN |
|---|---|---|
| Relative Strength Index (RSI) | 43.73 | 45.97 |
| Support Level | $0.98 | $0.66 |
| Resistance Level | $1.16 | $1.30 |
| Average True Range (ATR) | 0.07 | 0.07 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 15.97 | 65.26 |
Price Performance
Historical ComparisonAbout RDI Reading International Inc
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.